OVERVIEW

Target Discovery for RNA Therapeutics is organized by SMi Group Ltd and will be held on Sep 21, 2021 at Holiday Inn Kensington Forum, London, England, United Kingdom.

Target Audience:
Executives, Directors, VPs, Heads, Principals, Managers of:

• RNA Biology/Discovery
• Novel Therapeutic Modalities
• Innovation Technologies
• C-level Scientific Executives
• Formulation and Drug Delivery
• Clinical Research and Development
• Cell Biology

Overview:
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.

SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions.

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

The field of RNA therapeutics has been rapidly gaining momentum. In parallel, methodologies for early discovery have been taking a new form. Combining the now-accessible resources such as big data, multi-omics, and high-performance computing, this new ecosystem of R&D approaches has been surfacing.

This workshop will explore:
• Different perspectives on building a multi-disciplinary team
• Data-driven innovation for a biotechnology company
• Novel discovery platforms with horizontal applications
• Strategic insights in the field of RNA therapeutics